肝细胞癌患者外周血单个核细胞Foxp3 mRNA水平变化*

doi:10.3969/j.issn.1672-5069.2015.04.016

实用肝脏病杂志 ›› 2015, Vol. 18 ›› Issue (4): 395-398.doi: 10.3969/j.issn.1672-5069.2015.04.016

肝细胞癌患者外周血单个核细胞Foxp3 mRNA水平变化^*

杨智，陈洪涛，吴诗品

518020 广东省深圳市暨南大学第二临床医学院深圳市人民医院感染内科

收稿日期:2015-02-28 出版日期:2015-07-10 发布日期:2016-02-19
通讯作者: 吴诗品，E-mail:wupoem@126.com E-mail:ccyangzhi@sina.com
作者简介:杨智，女，36岁，硕士研究生，主治医师。主要从事感染性疾病临床与基础研究。E-mail:ccyangzhi@sina.com
基金资助:
广东省科技厅青年自然科学基金资助项目（编号：D2011283）

Foxp3 mRNA in peripheral blood mononuclear cells in patients with hepatocellular carcinoma

Yang Zhi，Chen Hongtao，Wu Shipin

Department of Infectious Disease，People's Hospital，Second Clinical Medical College Affiliated to Jinan University，Shenzhen 518020，Guangdong Province，China

Received:2015-02-28 Online:2015-07-10 Published:2016-02-19

摘要/Abstract

摘要： 目的检测初发现未治疗肝细胞癌（HCC）患者外周血单个核细胞（PBMCs）中 Foxp3 mRNA水平变化及其与血清AFP水平的关系。方法在HCC患者60例和健康人20例，采用RT-PCR法检测PBMCs中Foxp3 mRNA水平，常规检测血清AFP水平。结果 HCC患者和健康对照组外周血Foxp3 mRNA水平分别为（0.976±0.073）和（0.772±0.083），差异有统计学意义（P<0.01）；经Pearson相关性分析显示，HCC患者外周血Foxp3 mRNA水平与AFP水平呈正相关（r＝0.226，P＝0.025）。结论 HCC患者PBMCs 中Foxp3水平明显升高，对肿瘤的发生发展可能具有一定的预测作用。

关键词: 肝细胞癌, Foxp3, 外周血单个核细胞, 甲胎蛋白

Abstract: Objective To investigate Foxp3 mRNA levels in peripheral blood mononuclear cells （PBMCs） in patients with hepatocellular carcinoma（HCC） and explore its relationship with serum AFP levels. Methods 60 patients with HCC and 20 healthy persons were enrolled in this study. The Foxp3 mRNA in PBMCs was measured by RT-PCR and serum AFP was detected at the same time. Results There existed statistically significant difference in Foxp3 levels between patients with HCC and controls[（0.976±0.073） vs.（0.772±0.083），P<0.01]； Pearson correlation analysis showed positive correlation between Foxp3 levels in PBMCs and serum AFP levels in HCC patients（r＝0.226，P＝0.025）. Conclusion The Foxp3 levels in PBMCs in patients with HCC increase，which might help predict HCC development.

Key words: Hepatocellular carcinoma, Foxp3, Peripheral blood mononuclear cells, Alpha fetal protein

杨智，陈洪涛，吴诗品. 肝细胞癌患者外周血单个核细胞Foxp3 mRNA水平变化^*[J]. 实用肝脏病杂志, 2015, 18(4): 395-398.

Yang Zhi，Chen Hongtao，Wu Shipin. Foxp3 mRNA in peripheral blood mononuclear cells in patients with hepatocellular carcinoma[J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2015, 18(4): 395-398.

参考文献

[1] Llovet JM，Burroughs A，Bruix J. Hepatocellular carcinoma. Lancet，2003，362:1907-1917.
[2] Forner A，Llovet JM，Bruix J. Hepatocellular carcinoma.Lancet，2012，379:1245-1255.
[3] Jemal A，Murray T，Ward E，et al. Cancer statistics，2005. CA Cancer J Clin，2005，55:10-30.
[4] Budhu A，Forgues M，Ye QH，et al. Prediction of venous metastases，recurrence，and prognosis in hepatocellular carcinoma based on a unique immune response signature on the liver micro-environment. Cancer Cell，2006，10:99.
[5] Kaibori M，Kubo S，Nagano H，et al. Clinicopathological features of recurrence in patients after 10-year disease-free survival following curative hepatic resection of hepatocellular carcinoma. World J Surg，2013，37（4）:820.
[6] Sakaguchi S，Sakaguchi N，Asano M，et al. Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains（CD25）. Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J Immunol，1995，155:1151-1164.
[7] Pedroza-Gonzalez A，Verhoef C，Ijzermans JN，et al. Activated tumor-infiltrating CD+ regulatory T cells restrain antitumor immunity in patients with primary or metastatic liver cancer. Hepatology，2013，57（1）:183.
[8] 李巍，叶研硕，刘宏宇，等. 调节性Ｔ细胞在肝癌发生发展中的作用及机理. 中国实验诊断学，2013，17（12）:312-314.
[9] Zhao HQ，Li WM，Lu ZQ，et al. Roles of Tregs in development of hepatocellular carcinoma:A meta-analysis. World J Gastroenterol，2014，20（24）:7971-7978.
[10] Yagi H，Nomura T，Nakamura K，et al. Crucial role of FOXP3 in the development and function of human CD+25CD+4 regulatory T cells. Int Immunol，2004，16（11）:1643-1656.
[11] Shevach EM. Certified professionals:CD4（+）CD25（+） suppressor T cells. J Exp Med，2001，193（11）:41-46.
[12] Fontenot JD，Gavin MA，Rudensky AY.Foxp3 programs the development and function of CD4+CD25+ regulatory T cells. Nat Immunol，2003，4:330.
[13] Sakaguchi S，Sakaguchi N，Shimizu J，et al. Immunologic tolerance maintained by CD25+CD4+ regulatory T cells:their common role in controlling autoimmunity，tumor immunity， and transplantation tolerance. Immunol Rev，2001，182:18-32.
[14] Nishikawa H，Sakaguchi S. Regulatory T cells in tumor immunity. Int J Cancer，2010，127:759-767.
[15] Fu J，Xu D，Liu Z，et al. Increased regulatory T cells correlate with CD8 T-cell impairment and poor survival in hepatocellular carcinoma patients. Gastroenterology，2007，132:2328-2339.
[16] Hori S，Nomura T，Sakaguchi TJ. Control of regulatory T cell development by the transcription factor Foxp3. Science，2003，299:1057-1061.
[17] Levy MY，Sidana A，Chowdhury WH，et al. Cyclophosphamide unmasks an anti-metastatic effect of local tumor cryoablation. J Pharmacol Exp Ther，2009，330:596-601.
[18] Yamaguchi T，Sakaguchi S. Regulatory T cells in immune surveillance and treatment of cancer. Semin Cancer Biol，2006，16:115-23.
[19] Khazaie K，von Boehmer H. The impact of CD4+CD25+ Treg on tumor specific CD8+T cell cytotoxicity and cancer. Semin Cancer Biol，2006，16:124-36.
[20] Curiel TJ，Coukos G，Zou L，et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med，2004，10:942-949.
[21] Sasada T，Kimura M，Yoshida Y，et al. CD4+CD25+ regulatory T cells in patients with gastrointestinal malignancies:possible involvement of regulatory T cells in disease progression. Cancer，2003，98:1089-1099.
[22] Ormandy LA，Hillemann T，Wedemeyer H，et al. Increased populations of regulatory T cells in peripheral blood of patients with hepatocellular carcinoma. Cancer Res，2005，65:2457-2464.
[23] Stoop JN，van der Molen RG，Baan CC，et al. Regulatory T cells contribute to the impaired immune response in patients with chronic hepatitis B virus infection. Hepatology，2005，41:771-778.
[24] Wolf AM，Wolf D，Steurer M，et al. Increase of regulatory T cells in the peripheral blood of cancer patients. Clin Cancer Res，2003，9:606-612.
[25] Miller AM，Lundberg K，Ozenci V，et al. CD4+CD25high T cells are enriched in the tumor and peripheral blood of prostate cancer patients. J Immunol，2006，177:7398-7405.
[26] Frey DM，Droeser RA，Viehl CT，et al. High frequency of tumor-infiltrating FOXP3（+） regulatory T cells predicts improved survival in mismatch repair-proficient colorectal cancer patients. Int J Cancer，2010，126:2635-2643.
[27] Baecher-Allan C，Anderson DE. Regulatory cells and human cancer. Semin Cancer Biol，2006，16:98-105.
[28] Lee MK，Moore DJ，Jarrett BP，et al. Promotion of allograft survival by CD4+CD25+ regulatory T cells:Evidence for in vivo inhibition of effector cell proliferation. J Immunol，2004，172:6539.
[29] Casares N，Arribillaga L，Sarobe P，et al. CD+/CD25+ regulatory cells inhibit activation of tumor-primed CD4+T cells with IFN-gamma-dependent anti- angiogenic activity，as well as long-lasting tumor immunity elicited by peptide vaccination.J Immunol，2003，171:5931.
[30] Unitt E，Rushbrook SM，Marshal LA，et al. Compromised lymphocytes infiltrate hepatocellular carcinoma:the role of T-regulatory cells. Hepatology，2005，41:722-730.

肝细胞癌患者外周血单个核细胞Foxp3 mRNA水平变化^*

Foxp3 mRNA in peripheral blood mononuclear cells in patients with hepatocellular carcinoma

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	曹策, 郁义星, 王贝贝, 赵卫峰. 增强磁共振成像联合血清甲胎蛋白和脱-γ-羧基凝血酶原诊断肝细胞癌临床价值探讨[J]. 实用肝脏病杂志, 2019, 22(6): 896-899.
[2]	朱俊, 丁莹, 王世清, 张野, 刘野, 刘泽刚. 围手术期应用乌司他丁治疗对肝细胞癌患者肝切除术后外周血Th22细胞百分比和血浆白细胞介素-22的影响*[J]. 实用肝脏病杂志, 2019, 22(5): 720-723.
[3]	王刚, 赵洪波, 朱亚玲, 蒋保三, 张越美, 刁勇. 基于数据库分析肝细胞癌细胞XPO5基因水平变化及其临床意义*[J]. 实用肝脏病杂志, 2019, 22(5): 724-727.
[4]	戴青云, 王润东, 荚卫东. 术前预后营养指数评估肝细胞癌患者肝切除术后早期肿瘤复发价值探讨^*[J]. 实用肝脏病杂志, 2019, 22(4): 561-564.
[5]	杨富存, 尚怀学, 盖永浩. 钆塞酸二钠增强磁共振扫描诊断肝脏局灶性病变研究^*[J]. 实用肝脏病杂志, 2019, 22(4): 577-580.
[6]	彭新健, 肖玉辉, 许斯鼎, 石荣跃, 王耀政, 王瑜琳. 放射性肝损伤患者肝脏磁共振扩散加权成像表现特征分析[J]. 实用肝脏病杂志, 2019, 22(3): 373-376.
[7]	乔志忠. 超声造影定量分析鉴别肝脏局灶性结节性增生与原发性肝癌初步探讨[J]. 实用肝脏病杂志, 2019, 22(3): 421-424.
[8]	朱光曦（综述）, 文良志, 陈东风（审校）. 非酒精性脂肪性肝病相关肝细胞癌发病机制研究进展[J]. 实用肝脏病杂志, 2019, 22(3): 453-456.
[9]	王虎明,樊东升,徐杰,刘险峰,周宁,丽敏,包娜娜. 肝细胞癌患者癌组织miRNA-30c水平变化及其临床意义探讨^*[J]. 实用肝脏病杂志, 2019, 22(2): 248-251.
[10]	幸奠奎,程婧. ¹⁸F-FDG PET/CT检查指标预测肝细胞癌微血管侵犯临床价值研究^*[J]. 实用肝脏病杂志, 2019, 22(2): 252-254.
[11]	王秀清,马艳君,詹晋莉. 肝动脉化疗栓塞术联合超声引导下微波消融术治疗特殊部位原发性肝癌患者疗效及安全性分析 ^*[J]. 实用肝脏病杂志, 2019, 22(2): 260-263.
[12]	张小舟,帅领,王庆大,杨楠. 接受TACE治疗的肝细胞癌患者血清miR-335水平变化及其对预后判断的价值分析^*[J]. 实用肝脏病杂志, 2019, 22(2): 268-271.
[13]	王朝霞,关珂,付三仙,王慧杰. 肠内肠外联合营养支持治疗肝细胞癌患者围术期临床研究^*[J]. 实用肝脏病杂志, 2019, 22(2): 272-275.
[14]	赵西太综述,聂青和审校. 循环microRNA早期诊断肝细胞癌研究现状及方法学探讨[J]. 实用肝脏病杂志, 2019, 22(2): 297-300.
[15]	范建高. 2018年《实用肝脏病杂志》精彩回顾[J]. 实用肝脏病杂志, 2019, 22(1): 1-3.